ISPC vs OGN · rev $9.3M vs P/E 3.4, rev $6.40B
iSpecimen Inc (ISPC) versus Organon & Co (OGN) — a side-by-side from cached financials, not a winner call.
iSpecimen Inc (ISPC) is a diagnostics & research company listed on US.
Organon & Co (OGN) is a drug manufacturers - general company listed on US.
Latest reported ISPC revenue for 2024-12-31 was $9.3M. Net income was -$12.5M. Revenue was down 6.4% from 2023-12-31 to 2024-12-31. ISPC currently screens at market cap $4.4M.
Latest reported OGN revenue for 2024-12-31 was $6.40B. Net income was $864.0M. Revenue was up 2.2% from 2023-12-31 to 2024-12-31. OGN currently screens at market cap $2.52B and trailing P/E 3.4.
ISPC currently screens at market cap $4.4M. OGN currently screens at market cap $2.52B and trailing P/E 3.4.
Not investment advice. Open the ISPC and OGN stock pages for the full models.
Not investment advice.